具有Sigesbeckia glabrescens的抗炎活性的迪特尔类葡萄糖类
Lian-Yu Tang1, Ya-Zhao Zhang1, Yun Gao1
1School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
Fitoterapia
|April 7, 2024
概括
研究人员从Sigesbeckia glabrescens中分离出了六种新的二甲类葡萄糖. 化合物8在巨细胞研究中显示出显著的抗炎活性,表明潜在的治疗益处.
科学领域:
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 西格斯贝基亚 (Sigesbeckia glabrescens) 是一种具有传统药用历史的植物物种.
- 迪特尔类葡萄糖酸是一种具有多种生物活性的自然化合物.
- 了解S. glabrescens的化学成分和生物活性对于药物发现很重要.
研究的目的:
- 从Sigesbeckia glabrescens中分离和描述新型的二甲类葡萄糖体.
- 为了评估分离的化合物的抗炎潜力.
- 阐明这些天然产品的结构-活性关系.
主要方法:
- 使用色谱技术分离化合物.
- 通过广泛的光谱方法 (NMR,MS) 和电子循环二元化 (ECD) 计算来阐明结构.
- 在RAW 264.7巨细胞中使用脂聚糖 (LPS) 诱导的氧化 (NO) 生产的体外抗炎试验.
主要成果:
- 分离了6种新的二基糖化物 (化合物1-6) 和4种已知的化合物.
- 确定了新化合物的结构和绝对配置.
- 化合物1和8通过抑制NO的产生,显示出抗炎作用.
- 化合物8表现出显著的抑制活性 (IC50 = 14.20μM),表现优于积极对照的米诺环林.
结论:
- 西格斯贝基亚白是一种丰富的结构多样化的二氧化类葡萄糖的来源.
- 化合物8具有显著的抗炎性质,表明其作为治疗剂的潜力.
- 对化合物8的进一步研究可能会导致开发新的抗炎药物.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:06Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
01:24Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319